ABSTRACT Both genetic and nongenetic factors predispose to ulcer diathesis. At the mucosal level ulcers result from an imbalance between aggressive factors and mucosal defense. Ulcer therapy reduces aggressive forces, bolsters defense, or both. Gastric acid, the major aggressive factor, may have its secretion inhibited or it may be partially neutralized by antacids. H2 receptor antagonists competitively block histamine occupancy of H2 receptors on parietal cells, thereby preventing stimulation of adenylate cyclase, cAMP rises, and activation of protein kinase and H+/K+ATPase. Prostaglandins inhibit acid secretion largely by preventing histamineinduced cAMP rises. Proton pump inhibitors bind H+/K+ATPase. Antimuscarinics inhibit acetylcholine receptors on the parietal cell, thereby blocking Ca2+ entry and subsequent activation of protein kinase and the proton pump.
INTRODUCTION
The treatment of peptic ulcer disease (PUD) is best understood against a background of pathogenesis and pathophysiology. Since the advent of effective medical therapy with the introduction in 1976 of cimetidine, the first histamine H2 receptor antagonist, there have been remarkable advances in our understanding of how ulcers develop. In fact, the availability of effective therapy stimulated interest and research in ulcer disease generally, and gastric physiology specifically. Thus we currently enjoy the advantage of having various therapeutic options for ulcer patients and sufficient understanding of the relevant physiology and the disease itself to deploy the drugs rationally.
The purpose of this paper is to review the current understanding of the pathogenesis and pathophysiology of ulcer disease as a prelude to a discussion of the mechanisms ofaction and efficacy ofthe ulcerhealing drugs. 
PEPTIC ULCER DISEASE
Peptic ulcer disease appears to be a heterogeneous group of disorders having in common a hole in the gastroduodenal mucosa in the presence of gastric acid, but differing in the pathophysiology of ulceration. Both genetic and non-genetic factors are involved. Regarding events at the mucosal level, new information has been generated by animal studies of acute injury induced by a variety of methods. It is unclear if such studies are relevant to chronic ulcer disease in man. This article therefore relies largely on studies in man.
Genetic IqJirences. Genetic factors are involved in some patients, especially those with duodena1 ulcer (DU) (39) . Familial aggregation occurs and a positive family history is found in 20-50% of patients, compared with 5-1 5% in controls. The prevalence of PUD is increased 2-3-fold in first-degree relatives. Since a familial aggregation can result from environmental as well as genetic factors, studies in twins are invaluable in separating genetic and nongenetic influences. The concordance for ulcers in monozygotic twins is less than 100% but exceeds that of dizygotic twins. This suggests an interaction between genetic and environmental factors. 260 Several genetic markers have been identified in ulcer patients along with the relative risk for each marker. The risk is increased in individuals with blood group 0 and in those who do not secrete ABO antigens in saliva and gastric juice ("nonsecretors"). The relative risk for DU in those with blood group 0 and "nonsecretor" trait is multiplicative rather than additive. Nearly 50% of patients with DU have high serum pepsinogen 1 levels, an autosomal dominant trait. People with this trait are 5 times more likely to have DU than those without the trait. Those with high serum pepsinogen 1 levels have high maximum gastric acid outputs; this is a possible pathophysiologic link to peptic ulceration in such people.
The hypothesis of genetic heterogeneity is consistent with observations. This hypothesis holds that a disease is in reality a group of disorders with a similar clinical expression. Both genetic and nongenetic factors are involved and the pathophysiology may vary among patients (39) . Thus, ulcer patients with a strong family history, high pepsinogen 1 levels, and high maximum acid outputs have a different basis for their ulcers than those with no apparent familial predisposition who ingest large amounts of aspirin regularly. The concept also helps rationalize changes in ulcer pathogenesis over time; e.g., at one time stress may have been more important in ulcerogenesis than aspirin ingestion.
Nori-Getietic Factors. Various factors may increase the risk of developing an ulcer. Cigarette smoking is associated with an increased incidence of PUD, a high relapse rate, and resistance to therapy. Several physiological disturbances could explain ulcer formation in cigarette smokers (6). Nicotine reduces pancreatic bicarbonate secretion, pyloric sphincter pressure, and gastric mucus secretion. Moreover, cigarette smoking reduces gastric mucosal blood flow and gastric mucosal prostaglandin synthesis.
Aspirin use and gastric ulcers (GU) are strongly associated (6,23). Aspirin use 4 or more days weekly for 3 months or more increases the incidence of gastric ulcers, while daily use of 1 g of aspirin for 3 years to prevent myocardial infarction increases the prevalence 6-fold. Enteric-coated, but not buffered, aspirin reduces the risk significantly. Aspirin is directly toxic to gastric mucosa at a pH of 3.5 or less; it reduces gastric mucosal synthesis of prostaglandins by inhibiting cyclooxygenase activity. Nonsteroidal anti-inflammatory agents, including indomethacin, phenylbutazone, ibuprofen, naproxen, and fenoprofen, inhibit prostaglandin synthesis, causing acute gastric erosions and ulcers in man. Their role in causing chronic peptic ulcer disease is less clear.
The association of corticosteroids and ulcers is controversial. A review of 42 trials concluded that steroids are not ulcerogenic if taken for less than a month or in doses of less than the equivalent of 1 g of prednisone (5). A subsequent review of 72 trials concluded that steroids increase the ulcer risk in a dose-dependent manner (29) . The increased risk, however, is by a relatively small factor of 2.3, even with doses larger than the equivalent of 40 mg of prednisone daily. The influence of psychological factors in ulcerogenesis also is controversial. Ulcer perforations during air-raids (44) and occurrence of DU in people relocated (30, 45) support an association, but there is no evidence that people in stressful jobs have more ulcers (38) . People with PUD do not experience more stressful life events than do people without ulcers (35) , but they may perceive stressful life events more negatively (1 1). They may cope less well with stress and exhibit more personality disturbances, including hypochondriasis, excessive pessimism and dependence, immaturity, impulsivity, and feelings of social isolation and alienation (1 1). Contrary to popular belief, people with ulcers are not more likely to be hard-driving individuals; no "ulcer personality" has been found.
Although duodenal ulcers appear to be less frequent in people who consume a high fiber diet (40), there is no convincing evidence that diet causes ulcers. Similarly, there is no convincing evidence that ingestion of beverages containing alcohol or caffeine is ulcerogenic (23) .
Event at the Miicosa in Ulceration. Peptic ulcers result from an imbalance between aggressive forces and factors responsible for maintaining mucosal defense. The most carefully studied aggressive factor is gastric acid. Acid secretion may be increased in DU patients, although it usually is within the normal range. In GU patients, acid secretion may be reduced or normal. Thus, excessive aggressive forces are thought to be of greater importance in DU than GU.
Increased Aggressive Factors. Several ph y siologic defects may increase acid secretion or delivery of acid load to the duodenum in patients with DU, as listed in Table I (24); the frequency of defective feedback inhibition of acid secretion also is unknown (48) . Some physiologic defects, such as increased parietal cell mass, enhanced gastrin release by a protein meal, and rapid gastric emptying, appear to have a genetic basis (39).
Pepsin, bile acids, pancreatic juice, and lysolecithin may be aggressive factors in some patients. Pepsinogen is converted to pepsin by gastric acid at an optimum pH of 1.8-3.5. Pepsin's proteolytic activity could contribute to ulceration, but such an effect is difficult to separate from that of acid. The addition of pepsin to acid increases ulcerogenesis, but not to the extent that occurs if gastric juice is stimulated by secretagogues (20) . This suggests either that endogenous pepsins are more injurious than is reflected by their in vitro activity, or that additional factors are present in gastric juice, or both. Bile acids are injurious to the gastric mucosa. Ionized forms disrupt the gastric mucosal bamer to H+ by dissolving membrane lipids, and bile acids have other injurious effects on the bamer (8, 9). However, recent studies have found no difference in bile reflex into the stomach between normal controls and GU patients (2, 33) .
The agent most recently incriminated in ulcerogenesis is Camnpylobacter pylori. This bacterium is cultured frequently from antral biopsies in patients with antral gastritis and in patients with gastric and duodenal ulcers (14, 28). The bacteria appear to occupy a protected niche below the mucus layer of the gastric mucosa. C. pyjori have an ultrastructure and fatty acid combination that differs from other campylobacter species. They possess a powerful urease, and produce large amounts of extracellular catalase, which may be important virulence factors. A cause and effect relationship appears likely for antral gastritis (7), but not yet for ulcers.
Impaired Mi icosal Defense. Gas t roduoden a1 defense involves several factors (Table 11) (1 2). Mucus adheres to the surface of the gastroduodenal epithelia, forming an unstirred water layer through which H+ diffusion occurs at about one-fourth the rate of diffusion through unconstrained water (50) . Within and beneath the mucus gel, hydrogen ions from the stomach lumen are neutralized by bicarbonate ions secreted from the epithelial cells. This eliminates significant back diffusion of acid into epithelial cells.
Various defects in mucus in patients with PUD have been described (12). Gastric mucosal biopsies from patients with GU have reduced incorporation of precursor sugar into glycoproteins. Mucus taken from gastrectomy specimens of patients with GU contains more degraded mucus than normal, a finding also present to a lesser extent in patients with DU. It is not known if the mucus changes precede or follow peptic ulceration.
Bicarbonate secretion by the stomach and duodenum, together with mucus secretion, appears to be essential for mucosal protection (50) . Reduced gastric bicarbonate secretion has not been found (lo), but decreased bicarbonate secretion from the proximal duodenum was recently reported in DU patients (19). This reduction may be related to defective mucosal prostaglandin synthesis or release (see below). Patients with DU have a smaller pH gradient from lumen to surface epithelial cells than do non-ulcer patients (37) . This may be due to abnormal bicarbonate secretion or other mucosal defects in DU patients. It is not known if such defects precede or follow ulceration.
The role ofendogenous prostaglandins in mucosal defense has been clarified recently (16, 22) ; studies suggest a relationship between decreased mucosal prostaglandin synthesis and PUD. Prostaglandinmediated mucosal defense involves several mechanisms and varies with the prostaglandin employed. Mucus and bicarbonate secretion as well as cell resiitution are strmulated by E prostaglandins, and E and 1 prostaglandins and some lipoxygenase products enhance gastric mucosal blood flow. Duodenal mucosal content of PG12, PGF, (42), and PGE, (36) is subnormal in patients with DU, and duodenal prostaglandin synthesis does not rise normally in response to the acid load (1). Decreased synthesis of PGE2 has also been reported in GU patients (2 1, 23, 52); levels may be unusually low in the region of the stomach containing the ulcer (2 1). The efficacy of exogenous prostaglandin E compounds in healing peptic ulcers is only circumstantial evidence that mucosal prostaglandin deficiency is involved in peptic ulcer diathesis, since these agents also inhibit acid secretion at doses that convey mucosal protection. Nevertheless, available evidence supports the concept that prostaglandins are important in maintaining mucosal integrity and that they play a role in peptic ulcer disease in man. The precise nature of that role and its relative importance awaits clarification.
ULCER-HEALING DRUGS
Drugs promote ulcer healing by reducing gastric acid, bolstering mucosal defense, or both. Table I11 lists the drugs available for treating ulcers in the United States and some additional agents that are available in other countries. The drugs are divided between those that act primarily by reducing aggressive forces and those that act by bolstering defense.
Drugs inhibit acid secretion either by blocking receptors on parietal cells or inhibiting intracellular processes of acid secretion. The apical surface of parietal cell contains receptors for the major physiologic stimulants of acid secretion: gastrin, histamine, and acetylcholine (Fig. 1) . Activation of H2 receptors by histamine results in formation of cyclic AMP (43) . This presumably results from a change in receptor conformation which alters its interaction with a G protein, Gs. This protein binds the guanine nucleotide GTP, and then stimulates C, the catalytic subunit of adenylate cyclase. Cyclic AMP then activates specific protein kinases. The final step is the In contrast to histamine, gastrin and cholinergic agents act through calcium-dependent mechanisms. Cholinergic agents increase Ca2+ uptake through selective receptor-activated calcium channels (32) , which appear to differ from those present in muscle, nerve, and other tissues that are inhibited by calcium channel antagonists. Gastrin also increases Ca2+ entry (31), but it is not known if this is the only source of raised cytosolic Ca2+ following gastrin stimulation. Calcium-dependent kinases are then activated, followed by increased activity of the proton' pump.
The sites of acid inhibition by drugs acting at the parietal cell are illustrated in Fig. 2. H2 antagonists inhibit the cyclic AMP pathway; antimuscarinic and antigastrin agents block Ca2+-mediated acid secretion. Prostaglandins block histamine-induced rises of cyclic AMP (4, 27, 43 Antacids neutralize acid secreted into the gastric lumen. Because low doses of antacids have been found in some trials to accelerate DU healing (see below), it has been postulated that antacids may have an additional mode of action, such as stimulating endogenous prostaglandin synthesis in gastric mucosa (46) .
The mechanisms of action of sucralfate and tripotassium dicitrate bismuthate (colloidal bismuth subcitrate-CBS) are incompletely understood (1 5). Both agents bind proteins in the base ofulcers, thereby presumably protecting the ulcer bed from further acid-pepsin digestion. Sucralfate binds pepsin and bile acids. In animal models of acute mucosal injury it has been found to increase mucosal prostaglandin synthesis and secretion of mucus and bicarbonate. CBS may directly inactivate pepsin by chelation with bismuth. Its protective action is less clearly related to endogenous prostaglandin synthesis than is the case with sucralfate. CBS also clears the antral mucosa of C. pyfori, which, as discussed, are believed by some to cause antral gastritis and peptic ulceration (14, 28).
The prostaglandin analogues enhance mucosal defense in several ways in animal models of acute gastric mucosal injury (15). However, doses that heal ulcers in man inhibit acid secretion to a degree that can account for the healing. Thus it is not known if the mucoprotective properties contribute to ulcer healing. Cimetidine and ranitidine have mucoprotective properties that are independent of their antisecretory effect (15), but, as in the case of exogenous prostaglandins, it is not known if such effects contribute to ulcer healing. The efficacy of drugs and regimens in healing DU is shown in Table IV . Mosts agents heal ulcers in 70% or more of patients after 4 weeks of treatment at recommended doses (1 3). Healing usually exceeds 80% after 6 weeks and 90% after 8 weeks. Relief of pain is also comparable among the H2 blockers and, on average, slightly less rapid with sucralfate, misoprostol, and CBS (data not shown). Omeprazole heals duodenal ulcers in more than 90% of patients in 4 weeks, but the safety of omeprazole has not been established (26). Antacids were first shown to heal DUs when used in large doses, i.e., 30 ml of Mylanta I1 7 times daily (1,008 mmol) (34). More recently, small studies have shown that lower doses of magnesium aluminum-containing preparations are also effective (47, 49) . Gastric ulcer healing has been reported with all the agents listed in Table 111 . However, the evidence of,efficacy is well established in the case of the H2 antagonists and omeprazole, and least convincing in the case of antacids. On average, GUS probably heal more slowly than DUs; about 89% healing occurred after 12 weeks of cimetidine treatment in a particularly well-designed study (18). Over 90% of DUs heal after just 8 weeks of treatment.
